Crinetics Pharmaceuticals, Inc. — Director's Dealing 2019

Jan 25, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2019-01-22

Reporting Person: 5AM Ventures IV, L.P. (10% Owner)
Reporting Person: 5AM Co-Investors IV, L.P. (10% Owner)
Reporting Person: 5AM Partners IV, LLC (10% Owner)
Reporting Person: ROCKLAGE SCOTT M (10% Owner)
Reporting Person: DIEKMAN JOHN D (10% Owner)
Reporting Person: Schwab Andrew J. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-22	Common Stock	S	251667	$21.875	Disposed	3107642	Indirect
2019-01-22	Common Stock	S	10486	$21.875	Disposed	129483	Indirect

Footnotes

F1: These securities are held of record by 5AM Ventures IV, L.P. ("Ventures IV"). Following the transactions reported herein, 3,107,642 shares of Common Stock are held of record by Ventures IV.

F2: These securities are held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Following the transactions reported herein, 129,483 shares of Common Stock are held of record by Co-Investors IV.

F3: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.